The Effect of Dipeptidyl Peptidase 4 Inhibition on Growth Hormone Secretion in Women With Polycystic Ovarian Syndrome

Trial Profile

The Effect of Dipeptidyl Peptidase 4 Inhibition on Growth Hormone Secretion in Women With Polycystic Ovarian Syndrome

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs Sitagliptin (Primary)
  • Indications Cardiovascular disorders; Diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Mar 2018 Planned End Date changed from 1 Jan 2018 to 1 Jul 2019.
    • 01 Mar 2018 Planned primary completion date changed from 1 Jan 2018 to 1 May 2018.
    • 04 Jan 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top